{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:10:14Z","timestamp":1777590614689,"version":"3.51.4"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T00:00:00Z","timestamp":1597449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004423","name":"WHO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"name":"International PolioPlus Committee, Rotary International"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["D43 TW007585-01"],"award-info":[{"award-number":["D43 TW007585-01"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"CDC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Fractional dose (one-fifth of full intramuscular dose) of inactivated poliovirus vaccine (fIPV) administered intradermally is used as IPV dose-sparing strategy. We compared the rate of decline of poliovirus antibodies (PVA) in recipients of 2 doses of fIPV or IPV.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A community-based randomized controlled trial was conducted in Karachi, Pakistan. Children aged 14 weeks were randomized into fIPV or full IPV (study arms A, B) and received 1 vaccine dose at age 14 weeks and 1 at age 9 months. PVAs were measured at age 14, 18 weeks and 10, 21 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seroprevalence of poliovirus type 2 antibodies in 170\/250 (68%) children after 2 IPV or fIPV doses at age 10 months in A and B reached 100% vs 99% (P\u2005=\u2005.339), and at 21 months, 86% vs 67% (P\u2005=\u2005.004). Between age 10 and 21 months antibody log2 titers dropped from \u2265 10.5 to 6.8 in A and from 9.2 to 3.7 in B.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>There was a significant decline in antibody titers 12 months following the second IPV dose. The slope of decline was similar for full IPV and fIPV recipients. The results provide further evidence that fIPV is a viable option for IPV dose-sparing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT03286803.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaa504","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T04:07:17Z","timestamp":1596600437000},"page":"1214-1221","source":"Crossref","is-referenced-by-count":12,"title":["One-Year Decline of Poliovirus Antibodies Following Fractional-Dose Inactivated Poliovirus Vaccine"],"prefix":"10.1093","volume":"223","author":[{"given":"Ali Faisal","family":"Saleem","sequence":"first","affiliation":[{"name":"Aga Khan University, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ondrej","family":"Mach","sequence":"additional","affiliation":[{"name":"Polio Eradication Department, World Health Organization, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Tahir","family":"Yousafzai","sequence":"additional","affiliation":[{"name":"Aga Khan University, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaubina","family":"Kazi","sequence":"additional","affiliation":[{"name":"Aga Khan University, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attaullah","family":"Baig","sequence":"additional","affiliation":[{"name":"Aga Khan University, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Sajid","sequence":"additional","affiliation":[{"name":"Aga Khan University, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishali","family":"Jeyaseelan","sequence":"additional","affiliation":[{"name":"Polio Eradication Department, World Health Organization, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland W","family":"Sutter","sequence":"additional","affiliation":[{"name":"Polio Eradication Department, World Health Organization, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita K M","family":"Zaidi","sequence":"additional","affiliation":[{"name":"Aga Khan University, Karachi, Pakistan"},{"name":"Bill and Melinda Gates Foundation, Seattle, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,8,15]]},"reference":[{"key":"2021040816385915400_CIT0001","author":"Global Polio Eradication Initiative"},{"key":"2021040816385915400_CIT0002","author":"Centers for Disease Control and Prevention"},{"key":"2021040816385915400_CIT0003","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.aba1238","article-title":"Evolving epidemiology of poliovirus serotype 2 following withdrawal of the type 2 oral poliovirus vaccine","volume":"368","author":"Macklin","year":"2020","journal-title":"Science"},{"key":"2021040816385915400_CIT0004","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.1093\/infdis\/jiu222","article-title":"The new polio eradication end game: rationale and supporting evidence","volume":"210","author":"Sutter","year":"2014","journal-title":"J Infect Dis"},{"key":"2021040816385915400_CIT0005","author":"World Health Organization Strategic Advisory Group of Experts"},{"key":"2021040816385915400_CIT0006","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.vaccine.2017.03.008","article-title":"Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: a novel dose sparing immunization schedule","volume":"35","author":"Anand","year":"2017","journal-title":"Vaccine"},{"key":"2021040816385915400_CIT0007","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S2214-109X(16)30075-4","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia","volume":"4","author":"Clarke","year":"2016","journal-title":"Lancet Glob Health"},{"key":"2021040816385915400_CIT0008","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S1473-3099(11)70190-6","article-title":"Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6\u20139 months in Moradabad, India: a community-based, randomised controlled trial","volume":"12","author":"Estivariz","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2021040816385915400_CIT0009","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1086\/651611","article-title":"Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba","volume":"201","author":"Resik","year":"2010","journal-title":"J Infect Dis"},{"key":"2021040816385915400_CIT0010","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1056\/NEJMoa0909383","article-title":"Fractional doses of inactivated poliovirus vaccine in Oman","volume":"362","author":"Mohammed","year":"2010","journal-title":"N Engl J Med"},{"key":"2021040816385915400_CIT0011","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4103\/2224-3151.239418","article-title":"National introduction of fractional-dose inactivated polio vaccine in Sri Lanka following the global \u201cswitch.\u201d","volume":"7","author":"Gamage","year":"2018","journal-title":"WHO South East Asia J Public Health"},{"key":"2021040816385915400_CIT0012","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/infdis\/jiz026","article-title":"Poliovirus type 2 seroprevalence following full or fractional-dose of inactivated poliovirus vaccine in the period after Sabin type 2 withdrawal in Sri Lanka","volume":"219","author":"Gamage","year":"2019","journal-title":"J Infect Dis"},{"key":"2021040816385915400_CIT0013","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.15585\/mmwr.mm6647a4","article-title":"Fractional-dose inactivated poliovirus vaccine campaign\u2014Sindh Province, Pakistan, 2016","volume":"66","author":"Pervaiz","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021040816385915400_CIT0014","doi-asserted-by":"crossref","first-page":"859","DOI":"10.15585\/mmwr.mm6533a5","article-title":"Fractional-dose inactivated poliovirus vaccine immunization campaign\u2014Telangana State, India, June 2016","volume":"65","author":"Bahl","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021040816385915400_CIT0015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-4939-3292-4_8","article-title":"Standardized methods for detection of poliovirus antibodies","volume":"1387","author":"Weldon","year":"2016","journal-title":"Methods Mol Biol"},{"key":"2021040816385915400_CIT0016","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/B978-1-4557-0090-5.00034-3","article-title":"Poliovirus vaccine\u2014inactivated","volume-title":"Vaccines","author":"Vidor","year":"2013","edition":"6"},{"key":"2021040816385915400_CIT0017","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM200009143431103","article-title":"Trial of a supplemental dose of four poliovirus vaccines","volume":"343","author":"Sutter","year":"2000","journal-title":"N Engl J Med"},{"key":"2021040816385915400_CIT0018","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5114\/ceji.2018.77390","article-title":"Immunological memory cells","volume":"43","author":"Ratajczak","year":"2018","journal-title":"Cent Eur J Immunol"},{"key":"2021040816385915400_CIT0019","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1093\/cid\/ciy634","article-title":"Immune priming and long-term persistence of memory B cells after inactivated poliovirus vaccine in macaque models: support for at least 2 doses","volume":"67","author":"Bhaumik","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021040816385915400_CIT0020","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/infdis\/jiz124","article-title":"Rapid disappearance of poliovirus type 2 immunity in young children following withdrawal of oral poliovirus type 2 containing vaccine in Vietnam","volume":"220","author":"Huyen","year":"2019","journal-title":"J Infect Dis"},{"key":"2021040816385915400_CIT0021","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1086\/427810","article-title":"Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion","volume":"191","author":"Abbink","year":"2005","journal-title":"J Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa504\/33730548\/jiaa504.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/7\/1214\/36993029\/jiaa504.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/7\/1214\/36993029\/jiaa504.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:15:34Z","timestamp":1617927334000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/223\/7\/1214\/5892949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,15]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,8,15]]},"published-print":{"date-parts":[[2021,4,8]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa504","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,8,15]]}}}